Efficacy Study of CYT997 in Multiple Myeloma

Inclusion Criteria: * Diagnosis of multiple myeloma per International Working Group (IWG) criteria * Have received at least 1 but no more than 4 prior lines of therapy * Have failed to respond to the most recently administered anti-myeloma therapy * Have a life expectancy of at least 3 months * Eastern Cooperative Oncology Group (ECOG) performance status \< 3 * At registration absolute neutrophil count \> 1x10\^9/L and platelet count \> 50 x 10\^9/L unsupported * At registration bilirubin less than 1.5 x upper limit of normal and transaminases less than 2 x upper limit of normal and serum creatinine less than 0.19 mmol/L * Written informed consent * Must agree to adequate contraceptive measure if indicated Exclusion Criteria: * Patients with monoclonal gammopathy of undetermined significance * Known or suspected hypersensitivity to CYT997 * Patient with uncontrolled intercurrent illness * Active infections or other illnesses that precludes chemotherapy administration or patient compliance. * Pregnant or lactating women. * Patients who have received any other investigational agents in the last 3 weeks prior to the start of treatment. * Patients with the following conditions will be excluded: * myocardial infarction or stroke within 6 months * unstable angina pectoris or acute ischemic changes on ECG * history of diabetic retinopathy * symptomatic peripheral arterial disease * major surgery in the last 30 days * Patients with uncontrolled diarrhea despite optimal medication and those with any history of acute gastrointestinal bleeding * Patients with a baseline prolongation of the QTc interval of Common Terminology Criteria (CTC) Grade 1 (QTc \> 0.45-0.47 sec) or greater * Patients with impaired cardiac function or clinically significant cardiac diseases, including any one of the following: * left ventricular ejection fraction (LVEF) \< 45% as determined by multigated acquisition (MUGA) scan or echocardiogram; * complete left bundle branch block; * obligate use of a cardiac pacemaker; * congenital long QT syndrome; * history or presence of ventricular tachyarrhythmia; * presence of unstable atrial fibrillation (ventricular response \> 100 bpm). -Patients with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria; * clinically significant resting bradycardia (\< 50 bpm); * right bundle branch block + left anterior hemiblock (bifascicular block); * angina pectoris ≤ 3 months prior to starting study drug; * acute myocardial infarction (MI) ≤ 3 months prior to starting study drug; or * other clinically significant heart disease (e.g., congestive heart failure (CHF), uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen). * Patients currently receiving treatment with medications known to prolong the QTc interval and/or to induce Torsades de Pointes arrhythmia.